Compare L3Harris Technologies Inc (LHX) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
L3Harris Technologies Inc vs Sana Biotechnology Inc — how do they compare? L3Harris Technologies Inc trades at $280.5 (market cap $52.27B), while Sana Biotechnology Inc trades at $3.2 (market cap $873.84M). The key difference: L3Harris Technologies Inc is far larger — about 59.8× Sana Biotechnology Inc's market cap, and L3Harris Technologies Inc pays a 1.78% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| LHX | SANA | |
|---|---|---|
Market Cap | $52.27B | $873.84M |
Sector | Industrials | Health |
52-Week High | $378.48 | $5.92 |
52-Week Low | $263.09 | $2.68 |
Enterprise Value | $63.03B | $848.03M |
Dividend Yield | 1.78% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LHX trades at $280.57, down 0.51% today, with a bearish technical signal but strong fundamentals. The company reported Q1 2026 EPS of $2.72, beating estimates, and maintains robust cash flow. Recent contracts include a U.S. Space Force satellite deal and U.S. Army radio orders, supporting growth. Valuation metrics show a P/E of 30.62 and P/S of 2.36, with revenue rising to $21.87B in 2025.
Outlook is positive with a consensus price target of $367.50, implying 31% upside, driven by defense spending and execution. Risks include debt levels and geopolitical volatility. Analysts are 75% buy-rated, but technical indicators suggest near-term caution amid bearish moving averages.
SANA Biotechnology trades at $3.14, down 0.32% with bearish technical indicators despite strong analyst support. The company shows significant financial challenges with negative ROE of -147.41% and net income of -$244.17M for 2025, though cash burn improved from -$55M to -$12M in 2026. Recent positive developments include a Zacks upgrade to Buy and groundbreaking clinical data published in NEJM.
Investment outlook remains speculative with high execution risk given substantial losses, but strong analyst consensus (82% Buy ratings) reflects optimism about SANA's innovative cell therapy pipeline. Key risks include continued cash burn and clinical trial outcomes, while potential catalysts include successful product development in diabetes and CAR-T therapies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About L3Harris Technologies Inc
L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.
Read more on LHX →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
